Zimbabwe has declined a substantial American healthcare agreement worth $367m (£272m) over five years due to the United States' demand for sensitive data.
This rejection came to light following a official document from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official representative has since stated that the United States was requesting biological samples for research and commercial gain but was unwilling to guarantee the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for further dialogue to reach a deal acceptable to both sides so the nation's critical HIV programme can proceed.
Broader Background
This rejection follows a similar case in Kenya, where a court halted a related deal with the US following legal challenges were raised about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government agreements to enhance openness and accountability.
According to reports, 16 African countries have to date agreed to these new health pacts, representing over $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"Put simply, our nation would provide the raw materials for medical research without any assurance that the final treatments would be available to our citizens should a future disease outbreak emerge."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were upending frameworks already set up through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to deal with potential global health emergencies.
"This framework is designed to ensure that when a nation provides its information, the benefits – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to continued discussions with our American counterparts on how future co-operation could be structured in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body said it understood the government's concerns, but suggested that negotiations should continue considering a large portion of the nation's Aids initiatives were funded by foreign aid.
"Where technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
This impasse highlights the complex challenges between accepting much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.